Therapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model study

Basit Öğe Kaydı
dc.contributor.authorErbas, Oytun
dc.contributor.authorPala, Halil Gursoy
dc.contributor.authorPala, Emel Ebru
dc.contributor.authorUlkumen, Burcu Artunc
dc.contributor.authorAkman, Levent
dc.contributor.authorAkman, Tulay
dc.contributor.authorOltulu, Fatih
dc.contributor.authorAktug, Huseyhz
dc.contributor.authorYavasoglu, Altug
dc.date.accessioned2019-10-27T20:25:53Z
dc.date.available2019-10-27T20:25:53Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aim of our study is to investigate the effect of sunitinib on diabetes mellitus related-ovarian injury and fibrosis in rat models. An experimental diabetes mellitus model was created in 16 rats, and eight rats with normal blood glucose levels were included in control group (Group-1). The diabetic rats were divided into two groups:diabetic control group (water given) - Group-2 and sunitinib treatment group - Group-3. After four weeks, bilateral oophorectomy was performed and ovaries were examined histologically. The groups were compared by Student's t-test, analysis of variance (ANOVA) and Mann Whitney's U-test. There was a significant increase in no-medication (water given) diabetic rat's ovary (Group-2) in terms of follicular degeneration, stromal degeneration, stromal fibrosis and NF-kappaB immune-expression compared with control group normal rats' ovary (Group-1) (p < 0.0001). Stromal degeneration (p = 0.04), stromal fibrosis (p = 0.01), follicular degeneration (p = 0.02), NF-kappaB immune-expression (p = 0.001) significantly decreased in sunitinib-treated diabetic rat's ovary (Group-3) when compared with no-medication (water given) diabetic rat's ovary (Group-2) (p < 0.05). When we used sunitinib in the treatment of diabetic rats, ovarian injury, fibrosis and NF-kappaB immunoexpression decreased significantly. The effects of sunitinib in rat models give hope to the improved treatment of premature ovarian failure due to diabetes mellitus in humans.en_US
dc.identifier.doi10.3109/09513590.2015.1005593en_US
dc.identifier.endpage391en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue5en_US
dc.identifier.pmid25703256en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage388en_US
dc.identifier.urihttps://doi.org/10.3109/09513590.2015.1005593
dc.identifier.urihttps://hdl.handle.net/11454/42276
dc.identifier.volume31en_US
dc.identifier.wosWOS:000358972300011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdvanced glication end productsen_US
dc.subjectdiabetes mellitusen_US
dc.subjectNF-kappaBen_US
dc.subjectpremature ovarian failureen_US
dc.subjectreceptor of advanced glication end productsen_US
dc.subjectsunitiniben_US
dc.titleTherapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu